Usually a combination of an aromatase inhibitor (or fulvestrant) and a CDK4/6 inhibitor (such as palbociclib, ribociclib, or abemaciclib).
Metastatic breast cancer (MBC) treatment has undergone a significant shift in 2026, moving from generic protocols toward precision medicine tailored to specific tumor subtypes and genetic mutations. While MBC remains a chronic condition requiring lifelong management rather than a curable one, modern therapeutic strategies aim to maximize survival and maintain high quality of life. Current Standards of Care (2026) Download Traitement cancer sein mГ©tastatique pdf
As of early 2026, the European Commission approved inavolisib (Itovebi) for use in combination with palbociclib and fulvestrant for advanced forms of the disease. Usually a combination of an aromatase inhibitor (or